Clinical Trials
14
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
- Conditions
- Chronic Kidney Disease Stage 2Metabolic Dysfunction-Associated SteatohepatitisChronic Kidney Disease Stage 3
- Interventions
- Drug: Vonafexor low doseDrug: Vonafexor high dose
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT06939816
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT06425055
- Locations
- 🇺🇸
Dr Eric Wallace - University of Alabama, Birmingham, Alabama, United States
🇺🇸Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Dr Arnold Silva - Boise Kidney & Hypertension, Boise, Idaho, United States
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 26
- Registration Number
- NCT04465916
- Locations
- 🇦🇺
ENYO PHARMA Investigative site AU02, Brisbane, Australia
🇦🇺ENYO PHARMA Investigative site AU01, Melbourne, Australia
🇦🇺ENYO PHARMA Investigative site AU03, Melbourne, Australia
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT04365933
- Locations
- 🇭🇰
ENYO PHARMA Investigative site HK01, Hong Kong, Hong Kong
🇰🇷ENYO PHARMA Investigative site KR01, Busan, Korea, Republic of
🇨🇳ENYO PHARMA Investigative site TW03, Kaohsiung, Taiwan
Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose
- Conditions
- Healthy
- Interventions
- Drug: [14C]-EYP001a
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 6
- Registration Number
- NCT04037618
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
- Prev
- 1
- 2
- 3
- Next
News
NASH Treatment Market to Reach Significant Growth by 2032, Driven by Emerging Therapies
• The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. • This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. • Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. • The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.